1. Clinical Brochure of Oxantrazote, NSC 349174. Division of Cancer Treatment, National Cancer Institute, Bethesda, MD, 1987.
2. S. K. Frank, D. A. Mathiesen, M. Szurszewski. M. J. Kuffel, and M. A. Ames. Preclinical pharmacology of the anthrapyrazole analog oxantrazole (NSC-349174, piroxantrone).Cancer Chemother. Pharmacol. 23:213–218 (1989).
3. I. R. Judson. Anthrapyrazoles: True successors to the anthracyclines?Anti-Cancer Drugs 2:223–231 (1991).
4. A. Hantel, R. C. Donehower, E. K. Rowinsky, E. Vance, B. V. Clarke, W. P. McGuirs, D. S. Ettimger, D. A. Noe, and L. B. Grochow. Phase I study and pharmacodynamics of piroxantrone, a new anthrapyrazole.Cancer Res. 50:3284–3288 (1990).
5. M. M. Ames, C. L. Loprinzi, J. M. Collins, C. Van Haelst-Pisani, R. L. Richardson, J. Rubin, and C. G. Moertel. Phase I clinical pharmacological evaluation of pirozantrone hydrochloride (oxantrazole).Cancer Res. 50:3905–3909 (1990).